436 Trastuzumab- (H) and everolimus- (RAD001) containing regimens are safe and active when reintroduced in patients (pts) with HER2-overexpressing metastatic breast cancer (MBC) pre-treated with lapatinib
M. Campone, L. Gianni, C. Massacesi, C. Manlius, R. O'Regan, F. Dalenc, L. Vittori, Y. Zhang, T. Sahmoud, F. AndreVolume:
8
Year:
2010
Language:
english
DOI:
10.1016/s1359-6349(10)70458-4
File:
PDF, 46 KB
english, 2010